NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M

NEOGENOMICS INC

Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.
Net loss $27M vs $18M, up 53%; adjusted EBITDA $12.2M, down 9% from $13.4M.
Reaffirmed FY 2025 guidance: revenue $720-726M, net loss $(116)-(108)M, adj EBITDA $41-44M.
OpEx +12% YoY, includes $7.1M impairment charge on Trapelo held-for-sale.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.